<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163575</url>
  </required_header>
  <id_info>
    <org_study_id>Kece-2</org_study_id>
    <nct_id>NCT04163575</nct_id>
  </id_info>
  <brief_title>Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL</brief_title>
  <official_title>Phase I Study of T Cells Expressing an Anti-CD22 Chimeric Receptor in Children and Young Adults With B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kecellitics Biotech Company Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kecellitics Biotech Company Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, efficacy and duration of response of CD22 Chimeric
      Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed
      CD22+ haematological malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced
      Therapy Investigational Medicinal Product named CD22 Chimeric Antigen Receptor (CAR) T-cells
      (CD22 CAR T-cells) in patients with high risk, relapsed CD22+ haematological malignancies
      (Leukemia and lymphoma). Following informed consent and registration to the trial, patients
      will undergo an unstimulated leukapheresis for the generation of the CD22 CAR Tcells.
      Patients will receive the CD22CAR T-cells following lymphodepleting chemotherapy. The study
      will evaluate the safety, efficacy and duration of response of the CD22 CAR T-cells in
      patients with high risk relapsed CD22+ malignancies
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of each patient</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the toxicity profile of the CD22 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time of Anti-CD22 CAR T cells in vivo</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the presence of circulating CAR T cells with flow cytometry and real time PCR in patient blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor Effects</measure>
    <time_frame>Every 3 months post treatment up to 24 months</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of CD22 targeted CAR T cells.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) of CD22 targeted CAR T cells.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>experimental:1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental:2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental:3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>:Anti-CD22-CAR</intervention_name>
    <description>Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)</description>
    <arm_group_label>experimental:1</arm_group_label>
    <arm_group_label>experimental:2</arm_group_label>
    <arm_group_label>experimental:3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory B cell derived acute lymphoblastic leukemia(ALL), chronic
             lymphoblastic leukemia(CLL) and non-hodgkin lymphoma.

          2. KPS&gt;60.

          3. Life expectancy&gt;3 months.

          4. Gender unlimited, age from 2 years to 70 years.

          5. CD22 expression must be detected on greater than 15% of the malignant cells by
             immunohistochemistry or greater than 30% by flow cytometry.

          6. Patients who have failed at least one line of a standard treatment.

          7. No serious mental disorder.

          8. Patients must have adequate cardiac function(no cardiac disease, LVEF≥40% ), adequate
             pulmonary function as indicated by room air oxygen saturation of &gt;94%, and adequate
             renal function(Cr≤133umol/L).

          9. No other serious diseases(autoimmune disease, immunodeficiency etc.).

         10. No other tumors.

         11. Patients volunteer to participate in the research.

         12. Patients with history of allogeneic stem cell transplantation are eligible if at least
             100 days post-transplant, if there is no evidence of active GVHD and no longer taking
             immunosuppressive agents for at least 30 days prior to

        Exclusion Criteria:

          1. KPS&lt;50.

          2. Patients are allergic to cytokines.

          3. Central nervous system leukemia within 28 days.

          4. Uncontrolled active infection.

          5. Acute or chronic GVHD.

          6. Treated with T cell inhibitor.

          7. Pregnancy and nursing females.

          8. HIV/HBV/HCV Infection.

          9. Other situations we think improper for the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li xiangqun</last_name>
    <role>Study Chair</role>
    <affiliation>Kecellitics Biotech Company Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li xiangqun</last_name>
    <phone>086-15712867910</phone>
    <email>xiangqun_li@doingtimes.com</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>Leukemia</keyword>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

